Combined measles-malaria vaccine

Patent metadata

Field	Value
Publication number	US-9308250-B2
Application number	US-201414486578-A
Country	US
Kind code	B2
Filing date	Sep 15, 2014
Priority date	May 5, 2009
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum , the merozoite surface protein 1 (MSP-1) of P. falciparum , and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum , in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.

First claim

The invention claimed is:

1. A combined measles-malaria immunogenic composition comprising a recombinant measles virus which expresses CS malaria antigens and measles antigens capable of eliciting immune response both against measles and CS malaria wherein the nucleotide sequence of CS malaria antigen is SEQ ID NO:10.

2. The combined measles-malaria immunogenic composition as claimed in claim 1 , wherein the recombinant measles virus expresses single or different malaria antigens.

3. The combined measles-malaria immunogenic composition as claimed in claim 1 , wherein the recombinant measles virus expresses CS malaria antigen in both anchored and secreted forms.

4. The combined measles-malaria immunogenic composition as claimed in claim 1 , wherein the recombinant measles virus expresses CS malaria antigen in both anchored and secreted forms 3D7 strain and MAD 20.

5. The combined measles-malaria immunogenic composition as claimed in claim 1 , wherein the recombinant measles virus expresses CS malaria antigen in both anchored and secreted forms FCBI strain.

6. The combined measles-malaria immunogenic composition as claimed in claim 1 , wherein the malaria antigen is cloned between P and M or H and L protein of recombinant measles virus.

7. A measles vaccine virus vector comprising the nucleotide sequence of an antigen of malaria wherein the nucleotide sequence is SEQ ID NO: 10.

8. An isolated host cell comprising the vector of claim 7 .

9. The host cell as claimed in claim 8 , selected from E. coli or mammalian cell line.

10. The combined measles-malaria immunogenic composition as claimed in claim 1 , wherein the recombinant measles virus originating from a vaccine strain is derived from Edmoston Zagreb.

11. The combined measles-malaria immunogenic composition as claimed in claim 1 , wherein recombinant measles virus further encodes a protein with adjuvantic properties.

12. The immunogenic composition as claimed in claim 1 , further comprising an interleukin.

13. The immunogenic composition as claimed in claim 1 , which comprises one of the described recombinant measles malaria viruses or a mixture of two to several such viruses.

14. The immunogenic composition as claimed in claim 1 , being a component of a combined vaccine where the other components are rubella, mumps, varicella or another life attenuated vaccine virus, naturally attenuated or recombinant, alone or in combination.

15. The immunogenic composition as claimed in claim 1 , for parenteral administration comprising a suitable stabilizer.

16. The immunogenic composition as claimed in claim 1 , comprising a suitable stabilizer, adjuvant or a combination thereof wherein the stabilizer and adjuvant are such that the vaccine can be administered parenterally, intranasally, by inhalation, orally, transdermally or in a suppository.

17. A composition comprising the combined measles-malaria composition as claimed in claim 1 , comprising stabilizer, adjuvant or a combination thereof.

18. The composition as claimed in claim 12 , wherein the interleukin is interleukin 2.

19. The immunogenic composition according to claim 15 wherein the stabilizer is gelatin, human serum, albumin, sorbitol or a combination thereof.

Assignees

• Cadila Healthcare Ltd

Inventors

• Glueck Reinhard
• Fazio Agata
• Gianino Viviana
• Billeter Martin A

Classifications

• A61P31/22

  for herpes viruses · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P33/06

  Antimalarials · CPC title